Javier Pastor Francisco, Guarro Josep
Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Institut d'Investigació Sanitària Pere Virgili, Reus, Tarragona, España.
Rev Iberoam Micol. 2009 Mar 31;26(1):42-8. doi: 10.1016/S1130-1406(09)70007-5. Epub 2009 May 7.
Micafungin is an echinocandin antifungal drug recently approved for the treatment of candidiasis. The possibility of its clinical use against other invasive mycoses, has aroused the interest of numerous investigators in evaluating its efficacy in different animal models.
To critically review the current data on the use of micafungin in the treatment of invasive mycoses in animal models.
We searched the PubMed/Medline data base (National Library of Medicine) from 2005 to 2008, both inclusive, on the use of micafungin in the experimental treatment of the fungal infection.
Seven, of a total of 18 articles reviewed, were done in animal models of candidiasis and six in animal models of pulmonary or SNC aspergillosis. Similarly to the other echinocandins, caspofungin and anidulafungin, micafungin seems to exert a fungicidal activity against Candida albicans and Candida glabrata and a fungistatic activity against Aspergillus fumigatus. The paradoxical effect observed in lung tissue the experimental caspofungin treatment of aspergillosis has not been seen in the case of micafungin. The available data demonstrate a higher efficacy of micafungin versus fluconazole in the experimental treatment of C. albicans infections caused by strains susceptible in vitro to both drugs. To improve the efficacy of micafungin in the treatment of C. glabrata and A. fumigatus infections, several authors have tested different combined therapies, the combination of micafungin with amphotericin B being that showed the best results.
米卡芬净是一种棘白菌素类抗真菌药物，最近被批准用于治疗念珠菌病。其临床用于治疗其他侵袭性真菌病的可能性，引起了众多研究人员在不同动物模型中评估其疗效的兴趣。
严格审查目前关于米卡芬净在动物模型中治疗侵袭性真菌病的使用数据。
我们检索了2005年至2008年（含）期间美国国立医学图书馆的PubMed/Medline数据库中有关米卡芬净在真菌感染实验治疗中的使用情况。
在总共18篇综述文章中，7篇是在念珠菌病动物模型中进行的，6篇是在肺部或中枢神经系统曲霉菌病动物模型中进行的。与其他棘白菌素类药物卡泊芬净和阿尼芬净类似，米卡芬净似乎对白色念珠菌和光滑念珠菌具有杀菌活性，对烟曲霉具有抑菌活性。在实验性卡泊芬净治疗曲霉菌病时在肺组织中观察到的矛盾效应在米卡芬净治疗中未出现。现有数据表明，在体外对两种药物均敏感的菌株引起的白色念珠菌感染的实验治疗中，米卡芬净比氟康唑疗效更高。为提高米卡芬净治疗光滑念珠菌和烟曲霉感染的疗效，几位作者测试了不同的联合治疗方法，米卡芬净与两性霉素B联合使用显示出最佳效果。
